Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWQCRD)

Drug Name

L-2-Amino-4-(Guanidinooxy)Butyric Acid Drug Info

Synonyms

L-canavanine; canavanine; Canavanin; 543-38-4; 2-Amino-4-(guanidinooxy)butyric acid; L-2-AMINO-4-(GUANIDINOOXY)BUTYRIC ACID; UNII-3HZV514J4B; O-((Aminoiminomethyl)amino)-L-homoserine; O-carbamimidamido-L-homoserine; 3HZV514J4B; CHEMBL443732; CHEBI:609827; (L)-CANAVANINE; O-((Aminoiminomethyl)amino)homoserine; GGB; HSDB 3471; AI3-52153; L-Homoserine, O-((aminoiminomethyl)amino)-; Butyric acid, 2-amino-4-(guanidinooxy)-, L-; C5H12N4O3; L(+)-Canavanine; Tocris-0673; Spectrum_001137; Spectrum3_001206; Spectrum2_000800

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 439202
ChEBI ID: CHEBI:609827
CAS Number: CAS 543-38-4
TTD Drug ID: DMWQCRD

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Nitric-oxide synthase endothelial (NOS3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tilarginine acetate	DMZBGI8	Myocardial infarction	BA41-BA43	Phase 3	[2]
L-NAME	DM01SR6	Hypertension	BA00-BA04	Phase 2	[3]
ACCLAIM	DM0FGDO	Angina pectoris	BA40	Phase 2	[4]
VAS-203	DMKU93J	Brain injury	NA07.Z	Phase 2	[5]
MTR105	DMT0K4F	Hypotension	BA20-BA21	Phase 2	[6]
Autologous cell based gene therapy	DMQA1VT	Pulmonary hypertension	BB01	Phase 1	[7]
L-NIL	DM6Y49D	N. A.	N. A.	Terminated	[8]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[1]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[1]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nitric-oxide synthase endothelial (NOS3)	TTCM4B3	NOS3_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2	Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007 Apr 18;297(15):1657-66.
3	Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection. Vascul Pharmacol. 2009 Oct;51(4):253-61.
4	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
5	Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma. 2014 Oct 1;31(19):1599-606.
6	Nitric oxide synthase inhibitor (MTR-105) during open-heart surgery. A pilot double-blind placebo-controlled study of hemodynamic effects and safety. Cardiology. 2008;111(3):181-7.
7	Feasibility of using autologous transplantation to evaluate hematopoietic stem cell-based gene therapy strategies in transgenic mouse models of human disease. Mol Ther. 2002 Sep;6(3):422-8.
8	Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43.
9	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.